Abstract
Fibroblast growth factor 18 (FGF18) is a member of the FGF family and contributes to a broad range of biological events. The important role of the overexpression of FGF18 has been identified in the progression of several types of cancers. However, there is still little information on the biological role of FGF18 on clear cell renal cell carcinoma (ccRCC), which is of interest in investigating the biological functions of FGF18 in ccRCC. Our results showed that FGF18 was lowly expressed in ccRCC tissues compared to paired normal renal tissue from the TCGA database and clinical cohort of Huashan Hospital and that high expression of FGF18 correlated with a good prognosis in ccRCC patients. In addition, overexpression of FGF18 significantly inhibited the proliferation ability of ccRCC cell lines in vitro and in vivo. Gene set enrichment analysis (GSEA) identified epithelial-mesenchymal transition (EMT) involved in a high FGF18 expression group of ccRCC patients in the TCGA cohort, which was further validated with EMT related markers in FGF18 overexpressed ccRCC cell lines. Furthermore, FGF18 overexpression significantly inhibited the PI3K/Akt pathway in ccRCC cells. Taken together, this study concludes that FGF18 is of potential value as a target for ccRCC.
Highlights
Renal cell carcinoma (RCC) caused an estimated 65,340 new cases in 2018 and is the sixth most diagnosed neoplasm in men and tenth in women [1]
Fibroblast growth factor 18 (FGF18) were expressed significantly lower in the cancer tissue of kidney renal clear cell carcinoma (KIRC), LUAD, BLCA, and PRAD compared to normal tissues, while FGF18 were significantly up-regulated in the cancer tissue of COAD, LIHC, and STAD, compared to normal tissues
FGF18 Expression Correlates With Clinicopathological Characteristics of Clinical clear cell renal cell carcinoma (ccRCC) Tissues
Summary
Renal cell carcinoma (RCC) caused an estimated 65,340 new cases in 2018 and is the sixth most diagnosed neoplasm in men and tenth in women [1]. Clear cell renal cell carcinoma (ccRCC) or kidney renal clear cell carcinoma (KIRC) accounts for 70–85% histologic subtypes of RCC, which derives from the tubule epithelium of renal parenchyma [2]. CcRCC lacks conspicuous symptoms and approximately 25–30% of patients eventually suffer from metastatic RCC (mRCC) [3]. Approximately 40% of patients are resistant to conventional. FGF18 Inhibits ccRCC Progression chemotherapy and radiation therapy. There is an urgent need for further methods of recognizing these crucial biomarkers to facilitate early detection and counter the devastating progression of ccRCC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
